PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022

“PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in PD-1 and PD-L1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

PD-1 and PD-L1 inhibitors Understanding

PD-1 and PD-L1 inhibitors: Overview

PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can limit the development of the T cell response. The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation. The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. PD-1/PD-L1 inhibitors may be combined with other immunotherapies or traditional treatments to enhance efficacy relative to that using PD-1/PD-L1 therapy alone.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 and PD-L1 inhibitors R&D. The therapies under development are focused on novel approaches for PD-1 and PD-L1 inhibitors.

PD-1 and PD-L1 inhibitors Emerging Drugs Chapters

This segment of the PD-1 and PD-L1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PD-1 and PD-L1 inhibitors Emerging Drugs
• Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Tislelizumab was designed to bind to PD‑1, a cell surface receptor that plays an important role in allowing tumor cells to evade the immune system. Tislelizumab was first approved in China in late 2019 as a third-line treatment for classical Hodgkin lymphoma. In January 2021, Novartis signed a collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China.
• Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanized PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Dostarlimab is being investigated in recurrent or primary advanced endometrial cancer in combination with standard of care (SOC) chemotherapy and for stage III or IV non-mucinous epithelial ovarian cancer. It is also being evaluated in combination with other therapeutic agents for patients with advanced solid tumors or metastatic cancer. Dostarlimab was discovered by AnaptysBio and licensed to TESARO under a Collaboration and Exclusive License Agreement signed in March 2014.

Further product details are provided in the report……..

PD-1 and PD-L1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PD-1 and PD-L1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on PD-1 and PD-L1 inhibitors

There are approx. 70+ key companies which are developing the PD-1 and PD-L1 inhibitors. The companies which have their PD-1 and PD-L1 inhibitors drug candidates in the most advanced stage, i.e. Registration include, GlaxoSmithKline.
• Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

PD-1 and PD-L1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PD-1 and PD-L1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PD-1 and PD-L1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PD-1 and PD-L1 inhibitors drugs.

PD-1 and PD-L1 inhibitors Report Insights
• PD-1 and PD-L1 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

PD-1 and PD-L1 inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing PD-1 and PD-L1 inhibitors drugs?
• How many PD-1 and PD-L1 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for PD-1 and PD-L1 inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PD-1 and PD-L1 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for PD-1 and PD-L1 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• BeiGene
• GlaxoSmithKline
• Shanghai Junshi Biosciences
• Merck & Co
• Innovent Biologics
• Phio Pharmaceuticals
• Curocell
• Oneness Biotech
• Seneca Therapeutics
• Lyvgen Biopharma
• Jiangsu Hengrui Medicine
• Curis
• Sinocelltech
• Taizhou HoudeAoke Biomedical
• Y-Biologics
• Merck KGaA
• Celgene
• MedImmune
• Genentech

Key Products
• Tislelizumab
• Dostarlimab
• Toripalimab
• Pembrolizumab
• IBI-318
• PH 762-TME
• CRC-01
• SNA-01
• SVV-012
• Research programme: bispecific antibodies
• Camrelizumab
• Carrizumab
• CA-170
• SNA-02
• SCT-B07
• LP 002
• YBL-027
• Avelumab
• Durvalumab
• Atezolizumab